Trials / Completed
CompletedNCT00539734
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Electrophysiologic Changes After Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Prince of Songkla University · Academic / Other
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina. Ranibizumab (Lucentis) is a new drug that inhibits the growth of new vessels and has recently been approved by FDA for treating this condition. This study is carried out to evaluate the changes in retinal function after an injection of ranibizumab.
Detailed description
The functional changes of the retina can be recorded by an electroretinography (ERG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab | A single dose of 0.5 mg ranibizumab injected intravitreally. |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-12-01
- Completion
- 2009-02-01
- First posted
- 2007-10-04
- Last updated
- 2011-04-15
- Results posted
- 2011-04-08
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT00539734. Inclusion in this directory is not an endorsement.